Abstract: Oral formulations comprising at least one cannabinoid and at least one mouthfeel experience enhancer are described. For example, methods and materials for preparing a dissolvable lozenge comprising a combination of THC and CBD and Szechuan peppercorn or an extract thereof are provided.

Abstract: Materials and methods for improving the shelf-life of cannabinoids are described. For example, methods of improving the stability of cannabinoids during storage by applying one or more exogenous terpenes, terpenoids, or blend thereof to a cannabinoid-containing product, and packaging configured to stabilize a cannabinoid-containing product by preserving the applied one or more terpenes, terpenoids, or blend thereof are provided.

Abstract: A composition and methods for lubricating mucous membranes including reproductive tissue with a topical lubricant and at least one cannabinoid. Cannabis and cannabinoids are solubilized and combined with water-based personal lubricants.

Abstract: Oral formulations comprising at least one botanical extract of a psychotropic macrofungus and at least one mouthfeel experience enhancer are described. For example, methods and materials for preparing a dissolvable lozenge comprising a combination of psychoactive compounds such as psilocybin, psilocin, norpsilocin, baeocystin, norbaeocystin, aeruginascin, serotonin, bufotenin, ?-carboline alkaloids, muscarine, muscimol, muscazone, and ibotenic acid extracted from one or more psychotropic fungi and Szechuan peppercorn or an extract thereof are provided.

Abstract: Embodiments of a method and system for XR-assisted therapeutic psychedelic experience include receiving a set of inputs from a participant at an interaction engine associated with an XR system; at the interaction engine, determining a participant model for the participant; at the interaction engine, determining therapeutic goals for the participant; at the interaction engine, generating an interaction plan including a conversation component and an augmented or immersive element component, based on the participant model and the therapeutic goals; and executing the interaction plan with the XR system, thereby promoting a therapeutic psychedelic experience, such as a mystical-type experience, associated with improved outcomes for the mental or emotional well-being of the participant.

Abstract: The present invention provides aqueous formulations containing at least one cannabinoid, such as, for example, tetrahydrocannabinol (THC), cannabidiol (CBD), and a sulfoalkyl ether cyclodextrin (SAE-CD). The liquid formulations are substantially clear, sterilizable, and chemically and physically stable. The liquid formulations do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The SAE-CD-containing formulation provides significant advantages over other cyclodextrin-containing formulations of cannabinoids. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of at least one cannabinoid suitable for administration by injection. An SAE-CD-containing formulation of at least one cannabinoid can be provided in liquid form or as a reconstitutable solid. Solutions can be made either dilatable or non-dilutable with water at room temperature or under conditions typically encountered in the clinic.

Abstract: A non-tobacco, cannabis based moist snuff composition is provided. The composition includes an herbal component primarily made up of cannabis leaves and/or stems and a casing component. Methods for producing a nontobacco cannabis based moist snuff composition are also provided. The method includes the steps of separating the leaves and stems from the cannabis plant, drying and curing them and mixing them with a casing component.

Abstract: A medicament including cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) for mitigating and/or alleviating one or more symptoms associated with cessation of antidepressant medication are provided. For example, the present disclosure describes cannabis based medicinal extracts (CBMEs) and methods of treatment using the CBMEs to alleviate withdrawal effects associated with antidepressant medication cessation.

Abstract: A non tobacco, cannabis based moist snuff composition is provided. The composition includes an herbal component primarily made up of cannabis leaves and/or stems and a casing component. Methods for producing a nontobacco cannabis based moist snuff composition are also provided. The method includes the steps of separating the leaves and stems from the cannabis plant, drying and curing them and mixing them with a casing component.

Abstract: Materials and methods for making a water-soluble cannabinoid powder are provided. For example, the present disclosure provides a method for making a water-soluble cannabinoid powder by mixing a cannabinoid with a molten composition of a water soluble carrier, a hydrocolloid, and a surfactant, cooling the mixture, and grinding the cooled mixture. Formulations containing the water soluble powder to deliver an effective amount of the one or more cannabinoids to a subject in need thereof are also provided.

Abstract: Oral formulations comprising at least one cannabinoid and at least one mouthfeel experience enhancer are described. For example, methods and materials for preparing a dissolvable lozenge comprising a combination of THC and CBD and Szechuan peppercorn or an extract thereof are provided.

Abstract: Materials and method for mitigating the effects of acute cannabis intoxication are provided. For example, the present disclosure describes oral formulations comprising a peppercorn, a peppercorn substitute, or an extract thereof, a pharmaceutically acceptable excipient; and optionally CBD for use alleviating one or more unpleasant side effects of acute cannabis intoxication.

Abstract: The present disclosure describes materials and methods for providing the health benefits associated with chili peppers and cannabis to subjects in need thereof. For example, an oral formulation including at least one tissue from a fruit of the Capsicum genus, an extract therefrom, or a combination thereof, at least one cannabinoid, and a pharmaceutically acceptable excipient is provided. The oral formulation can be an oral spray, compressed tablet, or a candy-style lozenge.

Abstract: A packaging system and methods for the preservation of volatile chemicals in a product containing volatile chemicals is disclosed. The packaging system generally has one compartment adapted for the storage of the volatiles containing product in communication with a second compartment which contains a source of volatile chemicals such that the volatile chemicals disperse into the first compartment. The make up of the volatile chemicals in the second compartment are selected either to match the naturally occurring volatile chemicals in the product to be packaged or to complement the naturally occurring volatile chemicals in the product to be packaged. In this way, the naturally occurring volatiles content of the product can be preserved or odors and flavors that do not naturally occur within the product can be added. In some case, the product to be packaged is cannabis.

Abstract: A single dose vaporizable formulation including room temperature solid extracts and other botanical extracts and methods of processing and packaging single dose portions of vaporizable formulations. Also, methods of dispensing single dose portions, including segmented dose formulations and applicator-tab devices for vaporizers. A vaporizer having a heating chamber element with an indentation or cavity sized to receive a similarly-shaped, single dose vaporizable formulation.

Abstract: A multichannel vaporizer including multiple vapor sources and a user interface to modify a proportion of vapors from the vapor sources into a customized vapor to be delivered to the mouthpiece. Also, a method of providing a customized combination of vapors including adjusting a user interface to control an adjustable vapor manifold with a plurality of vapor paths defined between the plurality of vapor sources and a mouthpiece for issuing vapors.

Abstract: A composition and methods for lubricating mucous membranes including reproductive tissue with a topical lubricant and at least one cannabinoid. Cannabis and cannabinoids are solubilized and combined with water-based personal lubricants.

Abstract: An article and composition of matter including processed cannabis plant material with at least one cannabinoid, wherein the cannabis plant material has been processed to remove a material portion of one or more cannabinoids present in the cannabis plant material to a level sufficient to prevent an onset of negative consequences of THC consumption if said material portion is not removed.

Abstract: A substantially pure fraction of at least one cannabinoid is added to smokable or smokeless tobacco products to reduce the harm associated with tobacco use. The harm to be reduced includes irritation and carcinogenicity of tobacco. In a preferred embodiment a whole plant cannabis extract is mixed directly with the tobacco during the curing or manufacturing process. For cigarette applications the cannabinoids may be inserted into a cigarette filter, and/or paper. In other embodiments the cannabinoids are purified.

Abstract: A custom Cannabis extract dispenser for dispensing a Cannabis extract into a container is provided. The custom Cannabis extract dispenser includes several reservoirs for containing the various ingredients that will make up the final extract. The ingredients include purified cannabinoids, namely THC, CBD, minor cannabinoids, and various flavorants. A fluid management system in communication with a computer controller enables a user to select the amounts of the various ingredients desired in a custom Cannabis extract.